Predicting the Success of HPV Vaccines

Published on: 

Pharmaceutical Executive

Pharmaceutical Executive, Pharmaceutical Executive-10-25-2005, Volume 0, Issue 0

Will vaccines against cervical cancer be the blockbusters that Merck and GSK are predicting? Or will issues of cost-effectiveness and parental reluctance hold them back? The experts weigh in on the debate.